Assessing the efficacy of CIVID-19 vaccination: A critical analysis of the impact of COVID-19 vaccination on the risk of developing long-COVID and existing long-term symptoms' systematic review by Notarte et al. (2022)
Creators: name: Peduruhewa, Anuradha
Publisher: name: Zenodo
Year: 2024

description:  

Abstract

 

Background: Long COVID has emerged as a significant public health concern, with vaccination playing a potential role in prevention and symptom management.

Objective: This critical analysis examines Notarte et al.'s (2022) systematic review investigating the impact of COVID-19 vaccination on both developing long-term COVID and managing existing symptoms.

Methods: The study followed for Systematic Reviews and the Preferred Reporting Items Meta-Analyses guidelines, utilising comprehensive database searches and the Newcastle-Ottawa Scale for quality assessment. From the 2,584 articles, 17 studies were selected, analysing over 17 million vaccinated individuals and 37,000 post-infection vaccination participants.

Results: The review demonstrated that vaccination significantly reduced long COVID risk post-infection, with two-dose regimens showing greater efficacy than single-dose regimens. The effects on pre-existing long COVID symptoms varied across studies, ranging from improvement to no change or deterioration.

Conclusion: While Notarte et al.'s review provides valuable insights into the role of vaccination in long-term COVID prevention and management, limitations including inconsistent definitions and limited data on boosters highlight the need for standardised definitions and more robust longitudinal studies. These findings have important implications for public health vaccination.

 

 

Objective 

 

The study by Notarte et al. (2022) titled “Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review” The study scrutinised the effectiveness of the COVID vaccination. I am going to critically analyse this article and review the introduction, methodology, results, relevant policies, and future directions. This will shed light on the epidemiological characteristics of vaccination and COVID-19 outcomes.

Research question: What are the consequences of COVID-19 vaccination on the emerging COVID-19 infection or long-term COVID-19, and how does it influence the intensity and duration of pre-existing long-COVID syndrome?

 

Keywords: Long COVID, COVID-19 vaccination, systematic review analysis, vaccine efficacy, post-acute COVID-19 syndrome, public health policy

Ethical Compliance: This critical analysis of a published systematic review did not require ethical approval, as it did not involve human subjects or primary data collection.

Author Contributions: Anuradha Peduruhewa conceptualised the study design, conducted the critical analysis, wrote the manuscript, and approved the final version.

 Plain Language Summary

This study reviews the research on how COVID-19 vaccines affect the long-term COVID symptoms. It analysed a major research paper by Notarte and colleagues that looked at two key questions: Can vaccines prevent long COVID? Do vaccines help people with long-term COVID symptoms? The research found that vaccination, especially with two doses, can reduce the risk of developing long-term COVID after infection. However, the effect of vaccines on existing long-term COVID symptoms varied; some people got better, others stayed the same, and some felt worse. While this research provides important information about the use of vaccines to prevent and treat long COVID, more long-term studies are needed. This understanding will help healthcare providers and policymakers make better decisions about vaccine programs and support people with a long COVID.

 

Introduction

 

According to the World Health Organization (WHO) definition, symptoms appear within three months of initial infection with COVID-19 and last for a minimum of two months, and this is not related to any other underlying condition. COVID-19 immunisation prevents the covid infection by eradicating the remaining virus reservoirs and restoring the regular immune response. (NIHR, 2024) COVID-19 immunisation provides a control, predictable, and protective vaccine-based immunity over to SARS-CoV-2 virus, it can be boosted by natural immunity which can be from previous infections also called ‘hybrid immunity.’ (Tylicki, 2023) Multiple studies suggest that the COVID-19 vaccine has an impact on developing long-COVID, by a 50 to 75% reduction. However, the available evidence is limited and conflicting. (University of Oxford, 2024) Post-acute sequelae of the SARS-CoV-2 infection are also known as long-covid. Individuals with constant or new symptoms extend beyond the acute state of COVID-19 infection. (Notarte et al., 2022) Some studies show that patients with long-COVID are frequently older, probably female, and they need hospital admission and further clinical and medical treatment and assessment of the condition. (Sudre et al., 2020) According to the Notarte article explores the possible influence of COVID-19 vaccination on the risk of acquiring long-COVID symptoms, how vaccination may influence the prevalence of subsisting long-COVID symptoms, and the association between immunisation and COVID-19 infection, which is vital for understanding the long-term consequences of COVID-19 infection and the potential benefit of vaccination in alleviating these effects.

Multiple studies have provided valuable insights into the persuasiveness of vaccination in preventing COVID-19 infection and its associated complications. For example, the study of the BNT 16262 mRNA COVID-19 vaccine in a mass immunisation setting-imposed outcomes such as hospitalisation, severe illness, and death.  (Dagan et al., 2021) In this paper Notarte addresses the effect of the COVID-19 vaccine on both the likelihood of contracting the virus and the severity of its symptoms. Persistent symptoms affect several organ systems including the respiratory, cardiovascular, neurological, and psychological systems. Many people who recover from an acute infection are at risk for this serious health condition. To address the long-term health implications of COVID-19 knowledge of, the nature, frequency, and etiology are crucial. Research has examined the association between physiological and immunological aspects and emphasised the mechanism of these persistent symptoms of COVID-19 infection.  (Osiaevi et al., 2022; De Jong et al.,2023) Some studies have focused on the subtype and clinical clusters of long-covid delivering an understanding of the heterogeneity of symptoms and manifestation followed in person with long-term COVID-19 effects. (Magnusson et al.,2022; Reese et al.,2022)

This study emphasises the significance of understanding the correlation between COVID-19 immunisation and long-term COVID-19, as it may provide valuable insights for public health measures and enhance results. It analyzes the role of vaccination in reducing the risk of severe outcomes such as hospital admission or death, as well as its impact on an individual’s general health. (Notarte et al., 2022) Assessing the efficacy of COVID-19 immunisation in avoiding extended COVID is vital for public health since it has a substantial influence on people’s well-being and quality of life. Gaining a comprehensive understanding of the effectiveness of the vaccine is crucial for minimising the potential long-term health impact and alleviating strain on the health system. (Simon et al., 2021) To establish public trust and confidence in immunisation initiatives vaccination effectiveness must be evaluated. Studies on vaccine appropriateness and efficacy may address concerns, debunk disinformation, and enhance vaccination uptake rates, thereby curbing the spread of the virus and minimising long-term health consequences. (Pogue et al., 2020)

 

Methodology

 

A systematic review is a rigorous study that seeks to address a particular research issue by comprehensively assessing all relevant papers on a given subject, using transparent and replicable methodologies. (Turney, 2022)  To investigate the impact of immunisation on the risk of developing long-COVID and existing long-COVID symptoms, this article uses a systematic review of related studies as a methodology (Notarte et al., 2022) An observational cohort study with a prospective design used to investigate the covariates among subjects who were received different vaccines and utilise a binary logistic regression model to decide the association among vaccination factors and its outcomes. (Ayoubkhani et al., 2022) A prospective observational study was used to evaluate the COVID-19 immunisation on the health, symptoms, and immunological responses of individuals with protracted COVID-19 symptoms. Questionnaires, immunophenotyping tests, and statistical analyses were used for this evaluation. (Grady et al., 2024) The Epidemiological approach to this study selection of the affected population based on vaccinated or non-vaccinated individuals, COVID-19 survivors, individuals with long-term symptoms and the general population have been considered. (Davis et al., 2023) 

 

Search strategy and selection criteria

Sponsors maintain ethical values, scientific integrity, and openness in clinical trials. (NHS Health Research Authority, 2024) From data collection to publication clearance, the researchers handled everything without sponsor involvement. The database searches, publication elimination relevance assessments, duplication elimination, and methodological rigor assessments were rigorous. Authors, country, sample size. Vaccination status, vaccine type, and clinical data, mostly on COVID-19 symptoms before and after immunisation, were also collected. (Notarte et al., 2022)

The PRISMA statement guidelines improve systematic review and meta-analysis documentation in healthcare searches. The 27-item checklist and flow diagram include the title, abstract, introduction, methodology, results, discussion, and funding sources. Transparency and potential improve research quality and dependability. (Liberati et al., 2009) English-language human studies literature is reviewed using Boolean operation. The Population, Intervention, Comparison, and Outcome (PICO) method developed inclusive criteria; no ethics clearance was required for this review. (Notarte et al., 2022) Research ethics require rigorous adherence to rules to preserve participants’ rights, privacy, and well-being. This includes informed consent, confidentiality, participant protection, research integrity, legal compliance, conflicts of interest disclosure, and publishing ethics. (NMBI, 2015)

 

Inclusive and Exclusive criteria

The PICO strategy organises the clinical questions, search methods, articles, systematic review evaluation, heterogeneity, and subgroup analysis. This framework covers essential concepts, research methods, and systematic review criteria. It also distinguishes between likely variation and intervention factors. (Roever, 2018) Notrate et al. (2022) chose 18- year and older who tested positive for SARS-CoV-2 using a conventional COVID-19 test. The group was hospitalised and infection-free. He considered COVID-19 symptoms as a significant concern in this study. This suggests that COVID-19 immunisation may benefit patients at risk of chronic symptoms. This paper also helps people with chronic COVID-19 symptoms to find relief. COVID-19 immunisation will influence a diverse group with different ages, genders, comorbidities, immunological responses, and other clinical and demographic characteristics. From a vast collection of 2584 articles, this qualitative synthesis carefully selected 17 papers that met the highest standards of relevance and practicality. The exclusion criteria used to filter out irrelevant materials included editorials, opinion pieces, research conducted only in English, case reports, review publications, full-text studies, studies specifically centred on COVID-19 vaccines and long-term government summary reports, and study protocols without data. (Notarte et al., 2022)

It is important to consider whether someone has been vaccinated because this affects how well the vaccine works. Different age groups have different risks of long-term COVID-19, and each age group has a vaccine that works best. The type of vaccine that someone receives can help to prevent long-term COVID-19. (Nafilyan et al., 2023). It is  important to understand  that the specific strain of the virus is not the sole factor that determines the progression of the illness. Geographic variations, varying vaccination rates, healthcare systems, and the prevalence of COVID-19 contribute significantly to the long-term effects of COVID-19 (Wrigley-Field et al., 2021).

This population sample was compared with individuals who were not immunised against COVID-19. Data on post-covid or long covid symptoms were collected as an outcome of this study, characterised by physical, cognitive, respiratory, gastrointestinal, and mental health issues, assessed through interviews, phone calls, or computerised instruments. Different interpretations make it unclear for how long the symptoms should be monitored following the first infection. Research focusing only on changes in the immune system was excluded. (Notarte et al., 2022) Before and after receiving immunisation COVID-19 survivors’ symptoms are reviewed by observational cohort, cross-sectional, and case-control studies. None of the editorials, opinions, or correspondence articles were included. Two writers reviewed the databases, separated duplicates, and gathered information on authors, country, sample size, setting, vaccination status, vaccine type, clinical data, and post-COVID symptoms. They agreed to extract the data and invited a third author to resolve any differences. To ascertain eligibility, duplicates were removed, the titles and abstracts were examined, and the complete material was reviewed. This procedure sought to identify possible hazards and guide further studies.  (Notarte, et al., 2022) prevalence of COVID-19 and its correlation with vaccination status and disease severity were investigated using a prospective observational approach. The study was able to determine the impact of these factors after following a cohort of patients for a year and noticing patterns and correlations between variables. (Fatima et al., 2023) To investigate the occurrence and severity of long-term COVID-19 symptoms with correlation to vaccination, case-control, prospective cohort studies, and cross-sectional studies are carried out. Using this approach, the incidence of long-term COVID-19 symptoms, the consequences of vaccination compared to the unvaccinated, and the causes and symptoms of SARS-CoV-2 infection following immunisation were all discovered.  (Mumtaz et al., 2022)

This study provides critical data on long-term COVID-19 symptoms in distinct populations for focused public health interventions and successful immunisation efforts. Understanding how these symptoms appear in vaccinated and unvaccinated people and how they alter after vaccination for COVID-19 survivors can help guide immunisation efforts. Knowing the prevalence of long-term COVID-19 symptoms across demographic groups and how immunisation affects symptom improvement or worsening may inform public health measures. (Notarte et al., 2022) The COVID-19 pandemic has significantly impacted healthcare, vaccine delivery, transportation, logistics, wastewater monitoring, and public health measures. Reducing the environmental effects requires effective waste management, environmentally friendly vaccination distribution, and wastewater disposal. Long-term resilience and well-being must balance environmental sustainability with public health objectives. A sustainable future requires immediate attention to address environmental concerns (Hasija et al. 2022). 

 

Data analysis

The Newcastle-Ottawa Scale (NOS), a crucial tool in our field, was used to meticulously assess the quality of studies. It employs a star-grading system to scrutinise three fundamental aspects: the selection of the research group, comparability of these groups, and ascertainment of exposure or result.  The stars are assigned based on whether specific criteria are met in each area. These include how representative the exposed end non-exposed groups are, how accurately exposure is determined, how essential variables that could change the results are considered, how well the outcome is evaluated, and how much follow-up is performed. The scale has undergone improvement and expert evaluations, and it helps evaluate meta-analyses of nonrandomised trials. (Luchini et al., 2017) Notarte study’s methodological quality was assessed using the NOS. In case-control studies, a grade of 7 to 9 stars signifies excellent quality, whereas a rating of 5 to 6 stars indicates medium quality. Only a maximum of three stars may be provided in cross-sectional studies. Two authors initially assessed the methodological quality, and a third researcher resolved the disagreements. Meta-analysis was deemed unsuitable owing to significant heterogeneity across the studies. The data were analysed to examine population demographics, vaccination status, and the quality of the methodology used. (Notarte et al., 2022)

 

Results 

 

Odds ratio (OR) was a crucial measure in our study. It accurately measures the correlation between COVID-19 immunisation and long-term COVID-19 risk. The OR enabled us to determine the likelihood of long-term COVID-19 by comparing the presence of the COVID-19 vaccine to the possibility of an event happening without it. (Bland and Altman, 2020) The research is divided into two groups: one group examines individuals who received the vaccine before infection (vaccine-before, infection, long COVID), while the other group focus on individuals who were infected before receiving the vaccine (infection, long COVID, vaccine-after) According to six studies, vaccination significantly lowers the risk of long-term COVID-19 symptoms following acute infection.  According to research, mRNA, vector, and nonspecific vaccination may reduce COVID-19 symptoms. However, further studies are required to determine its long-term effectiveness. (Notarte et al., 2022) The current study reveals that the COVID-19 vaccination type may not affect breakthrough infections. However, an individual’s immune response, vaccination duration, and viral evolution may be more important. Further studies are required to confirm these results. (WHO, 2024; CDC, 2020) Initial evidence suggests that administering two doses of the vaccine may be more efficacious in lowering COVID-19 long-term risk than a single dose. Further research is required to confirm this hypothesis. (Notarte et al., 2022) Research is underway to explore the potential of administering more vaccine doses before infection, which could offer enhanced protection against the long-term risks associated with COVID. Early findings indicate that one dose of the vaccine decreased the risk of long-term COVID-19 by 21%, whereas two doses reduced it by 59%, and three or more doses reduced it by 73% in comparison to persons who were not vaccinated. (Hall, 2024) Many studies indicate that immunity can be established approximately 14 days after immunisation. The mRNA vaccines from Pfizer and Moderna reached their maximum efficacy approximately two months after the first dose. Additionally, the protection rate against severe COVID-10 outcomes increases rapidly, with efficiency shown as soon as one month after completing the full vaccination series. (Higdon et al.,2022) Vaccine affects pre-existing long-term COVID-19 symptoms differently in 11 trials. Studies on immunisation and long-COVID symptoms varied. Several studies reported symptoms, while others found no change or deterioration, which shows the complexity of the association between immunisation and long-COVID-19 symptoms. An increased body antibody titre ratio causes an excessive immune response to vaccination, which may be the reason for its worsening.  (Notarte et al., 2022) A UK study found that vaccination after SARS-CoV-2 infection reduces long-term COVID symptoms in the first few months. Around 30-40% of long-term COVID patients reported improvements in symptoms. However, the mechanism underlying this improvement remains unclear. Some patients experienced no change, whereas others reported worsening symptoms. (Katella, 2021)

 

Discussion

 

Policies 

Vaccination before SARS-CoV-2 infection reduces the risk of developing long-term COVID-19 symptoms after an acute infection, suggesting that it could be an effective preventive public health strategy. Preliminary evidence suggests that two doses may be more protective than one, supporting the complete primary vaccination series recommendation. Primary vaccination by public health authorities, especially with two doses, reduces the societal and economic burden of long-term COVID-19 cases. (Notarte et al., 2022) The search results prioritise COVID-19 vaccination for high-risk groups most susceptible to catastrophic consequences and aim to save hospital capacity, this prioritisation is determined by vaccine supply and characteristics rather than specifically targeting at risk of protracted COVID-19. (European Centre for Disease Prevention and Control, 2020) The search findings indicate the need for enhanced monitoring and surveillance mechanisms to monitor long-term COVID-19 symptoms in vaccinated people. This will help resolve gaps in the data and limit the comprehension of the long-term impact of COVID-19 vaccination. (Schraer, 2022; Notarte et al., 2022) It is essential to effectively explain the advantages of COVID-19 immunisation via public health messaging while also acknowledging and conveying its limits and uncertainties. Encouraging vaccination uptake may be achieved by establishing trust, presenting scientific evidence, and customising information for the target groups. (Fullerton et al., 2022)

Policymakers and health authorities aim to establish a uniform definition of long-term COVID-19 to maintain uniformity in research, clinical practice, and practice, identification, treatment, and monitoring of persistent symptoms. (Notarte et al., 2022) The revised healthcare guidelines may offer healthcare professionals up-to-date information on the changing evidence about the COVID-19 vaccination and the long-term effects of the virus. This would require continuous monitoring and research to resolve any gaps or limitations in the available data under the suggestions obtained from the search results. (Lam et al., 2024; Notarte et al., 2022) The search findings underscore the need for rigorous studies on the enduring effects of COVID-19 immunisation on people already experiencing symptoms. Financing such research may provide valuable insights for policymaking and public health initiatives. (NHS Health Research Authority, 2024)

 

Limitation

Most studies on long-covid-19 have deviated from the WHO clinical classification. They investigated persistent symptoms following acute SARS-CoV-2 infection without a conventional diagnosis. This technique lacks the complete assessment required to comprehend these illnesses. There is little evidence regarding vaccination boosters and SARS-CoV-2 strains. Hospitalisation, sex, and age differences were not considered consistently. Most studies assessed immediate effects, whereas two included lengthy periods. Possible discrepancies in the study groups and criteria affected the impact of vaccination on pre-existing long-COVID symptoms.

 

Strength

The authors conducted an extensive literature search to identify publications examining the effects of COVID-19 immunisation on the risk and symptoms of long-term COVID-19. The researchers chose papers from both peer-reviewed published journals and preprint articles and evaluated their methodological quality using the Newcastle-Ottawa Scale. The evaluation, which was conducted on a massive scale, included more than 17 million individuals in the vaccine group before the infection group and approximately 37,000 in the immunisation group after the long COVID group. The study highlighted areas lacking data and conducted a narrative synthesis to guide future research on COVID-19 immunisation and long-term COVID-19. 

 

Recommendation

 

This study aimed to explore the link between COVID-19 immunisation and its long-term consequences. This suggests strategies to decrease the risk of long-term COVID-19. These include administering the vaccine before infection and instituting a two-dose vaccination regimen to increase defense against long-term sequelae. Further research is needed to understand the possible long-term effects of COVID-19 vaccination. Comprehensive investigations, including monitoring after treatment, characterising long-term effects across all demographics, assessing the effectiveness of additional doses, studying immune responses, assessing the effectiveness of additional doses, studying immune responses, conducting comparative analyses, and evaluating healthcare usage, can help us achieve this goal. We will collaborate to gain a better understanding of the long-term effects of COVID-19 vaccination. To better understand the impact of vaccination on extended consequences, research should examine enquiries related to COVID-19. This can help inform public health regulations and improve approaches to preventing, managing, and treating the disease.

Given the widespread impact of the COVID-19 pandemic, it is important to prioritise the study of the virus’s long-term effects on patients. Defining long-term COVID-19 and closely monitoring specific groups of individuals will help us better understand how viruses affect their health. Assessing the effectiveness of booster shots and vaccines against variants, researching immune responses, and evaluating healthcare applications are crucial steps. These efforts will contribute to the development of more effective prevention and treatment methods and will deepen our understanding of the virus. As this study highlights, extensive research is crucial to better understand the intricate correlation between vaccination and the long-term effects of COVID-19. This goal can be accomplished by incorporating randomised controlled trials (RCTs), comparative effectiveness research studies, population-based surveillance, registry studies, biobanking, biomarker analysis, and partnerships with national health agencies and international organisations. These efforts aim to enhance our understanding of the impact of COVID-19 immunisation on long-term health outcomes. Evidence-based public health interventions can be developed, and measures can be optimised to mitigate the effects of long-term COVID-19 on individuals and health systems worldwide.

 

References 

Ayoubkhani, D., Pawelek, P. and Gaughan, C., 2022. 'Trajectory of long covid symptoms after covid-19 vaccination: a community-based cohort study'. British Medical Journal, 376, e069676.

Bland, J.M. and Altman, D.G., 2000. 'Statistical Notes: Odds ratio'. British Medical Journal, 320(7247), pp.1468-1469.

British Heart Foundation, 2023. Long COVID. [online] Available at: https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/long-covid [Accessed 23 September 2024].

Centers for Disease Control and Prevention, 2020. COVID-19 vaccination. [online] Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html [Accessed 23 September 2024].

Dagan, N., Barda, N. and Kepten, E., 2021. 'BNT162B2 mRNA COVID-19 vaccine in a nationwide mass-vaccination setting'. New England Journal of Medicine, 384(15), pp.1412-1423.

Davis, H.E., McCorkell, L. and Vogel, J.M., 2023. 'Long COVID: Major findings, mechanisms and recommendations'. Nature Reviews Microbiology, 21(3), pp.133-146.

De Jong, C.M.M., Barco, S. and Gómez-Mesa, J.E., 2023. 'Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism'. European Respiratory Journal, 61(4), p.2300171.

European Centre for Disease Prevention and Control, 2020. COVID-19 vaccination and prioritisation strategies in the EU/EEA. [online] Available at: https://www.ecdc.europa.eu/en/publications-data/covid-19-vaccination-and-prioritisation-strategies-eueea [Accessed 23 September 2024].

Fatima, S., Ali, M. and Khattak, M., 2023. 'Association between long COVID and vaccination: A 12-month follow-up study in a low- to middle-income country'. PLOS ONE, 18(11), e0294780.

Fullerton, M.M., Ross, L.E. and Harrison, R., 2022. 'Challenges and recommendations for COVID-19 public health messaging'. BMJ Open, 12(4), e054635.

Grady, C.B., Klein, J. and Lucas, C., 2024. 'Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with long-term COVID'. Preprint. medRxiv.

Hall, S., 2024. Vaccination dramatically lowers the risk of long-term COVID. Scientific American. [online] Available at: https://www.scientificamerican.com/article/vaccination-dramatically-lowers-long-covid-risk [Accessed 23 September 2024].

Hasija, V., Patial, S. and Raizada, S., 2022. 'The environmental impact of mass coronavirus vaccinations'. Science of the Total Environment, 813, 151881.

Higdon, M.M., Wahl, B. and Jones, C.B., 2022. 'Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant'. The Lancet Infectious Diseases, 22(8), pp.1114-1116.

Katella, K., 2021. Why vaccines may help some with long COVID. Yale Medicine. [online] Available at: https://www.yalemedicine.org/news/vaccines-long-covid [Accessed 23 September 2024].

Lam, I.C., Wong, J.Y. and Chen, D., 2024. 'Persistence of risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection'. Nature Communications, 15(1), pp.1-15.

Liberati, A., Altman, D.G. and Tetzlaff, J., 2009. 'The PRISMA statement for reporting systematic reviews and meta-analyses of studies'. British Medical Journal, 339, b2700.

Luchini, C., Stubbs, B. and Solmi, M., 2017. 'Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale'. World Journal of Meta-analysis, 5(4), pp.80-84.

Magnusson, K., Kristoffersen, D.T. and Suren, P., 2022. 'Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants'. Nature Communications, 13(1), 7475.

Mumtaz, A., Hasan, M. and Hamid, T., 2022. 'COVID-19 Vaccine and Long COVID: A Scoping Review'. Life, 12(7), 1066.

Nafilyan, V., 2023. COVID-19 vaccine effectiveness estimated using Census 2021 variables, England. Office for National Statistics. [online] Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/covid19vaccineeffectivenessestimatedusingcensus2021variablesengland/31march2021to20march2022 [Accessed 23 September 2024].

National Institute for Health and Care Research (NIHR), 2024. COVID-19 vaccines effective in reducing long COVID symptoms. [online] Available at: https://www.nihr.ac.uk/news/covid-19-vaccines-effective-in-reducing-long-covid-symptoms/35233 [Accessed 23 September 2024].

NHS Health Research Authority, 2024. Roles and responsibilities. [online] Available at: https://www.hra.nhs.uk/planning-and-improving-research/research-planning/roles-and-responsibilities [Accessed 23 September 2024].

Notarte, K.I., Catahay, J.A. and Velasco, J.V., 2022. 'Impact of COVID-19 vaccination on the risk of developing long-COVID and existing long-COVID symptoms: a systematic review'. EClinicalMedicine, 53, 101624.

Nursing and Midwifery Board of Ireland (NMBI), 2015. Ethical conduct in research. [pdf] Dublin: NMBI.

Osiaevi, I., Berra, G. and Greco, A., 2022. 'Persistent capillary rarefication in long COVID syndrome'. Angiogenesis, 26(1), pp.53-61.

Pogue, K., Jensen, J.L. and Stancil, C.K., 2020. 'Influences on attitudes regarding potential covid-19 vaccination in the united states'. Preprint. Research Square.

Reese, J., Blau, H. and Mote, N., 2022. 'Generalisable Long COVID Subtypes: Findings from the NIH N3C and RECOVER Programs'. Preprint. medRxiv.

Roever, L., 2018. 'PICO: Model for Clinical Questions'. Evidence-Based Medicine, 3(2), pp.115-118.

Schraer, R., 2022. Vaccines: What we know about long-term safety. BBC News. [online] Available at: https://www.bbc.co.uk/news/health-60468900 [Accessed 23 September 2024].

Simon, M.A., Luginbuhl, R.D. and Parker, R.H., 2021. 'Reduced incidence of long-COVID symptoms related to administration of COVID-19 vaccines'. Preprint. medRxiv.

Sudre, C.H., Murray, B. and Varsavsky, T., 2020. 'Attributes and predictors of Long-COVID'. Preprint. medRxiv.

Turney, S., 2022. Systematic Review | Definition, Examples & Guide. Scribbr. [online] Available at: https://www.scribbr.co.uk/research-methods/systematic-reviews/ [Accessed 23 September 2024].

Tylicki, L., 2023. 'Immunity after Vaccination against COVID-19'. Vaccines, 11(11), 1723.

University of Oxford, 2024. COVID-19 vaccines found to be effective in reducing long COVID. [online] Available at: https://www.ox.ac.uk/news/2024-01-12-covid-19-vaccines-found-be-effective-reducing-long-covid-symptoms [Accessed 23 September 2024].

World Health Organization, 2024. Coronavirus disease (COVID-19) pandemic. [online] Available at: https://www.who.int/europe/emergencies/situations/covid-19 [Accessed 23 September 2024].

World Health Organization, n.d. Coronavirus disease (COVID-19): Vaccines and vaccine safety. [online] Available at: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-%28covid-19%29-vaccines [Accessed 23 September 2024].

Wrigley-Field, E., Kates, J. and Khazanchi, R., 2021. 'Geographically targeted COVID-19 vaccination is more equitable'. Science Advances, 7(40), eabj2099.